Doctor Remortgages House to Fund Rapamycin Exercise Trial After Crowdfunding Fails

Dr. Brad Stanfield's four-year journey to fund a rapamycin and exercise clinical trial reveals the significant challenges facing longevity research. In 2021, he announced plans to crowdfund $600,000 for this study, motivated by rapamycin's impressive lifespan extension effects in mice. However, since rapamycin is off-patent (discovered in the 1960s), traditional pharmaceutical investment isn't viable due to lack of return potential.

After two years of crowdfunding efforts, Stanfield had raised only $80,000 from his YouTube community of 40-50,000 subscribers. Recognizing the need for alternative funding, he created his own supplement company in 2023, inspired by the COSMOS-Mind study showing cognitive benefits from multivitamin supplementation. His custom formulation included specific forms and doses of nutrients, excluding vitamin A and E while adding TMG.

Just as the supplement business launched, two generous viewers offered to fund the entire trial through Lifespan.io. However, during stock market volatility, the second donor couldn't fulfill their commitment, leaving a $150,000 gap. Meanwhile, Stanfield's supplement business faced unexpected scaling challenges, including inventory shortages and high operational costs that required constant reinvestment.

Refusing to abandon the project, Stanfield made the difficult decision to remortgage his family home and borrow against his business to complete funding. The 40-participant study successfully completed data collection in January 2025, with the manuscript submitted for peer review in July. This personal sacrifice underscores both the importance of rapamycin research and the funding obstacles facing longevity science, while demonstrating the lengths researchers must go to advance this critical field.